Why the FDA should take more chances on riskier drugs

Oct 6, 2015, 10:37 by Michael Croft

Pharmalot | An MIT study challenges the FDA to be more flexible in drug approvals, altering the odds based on the severity of the disease and availability of treatments.

October 06, 2015 | An MIT study challenges the FDA to be more flexible in drug approvals, altering the odds based on the severity of the disease and availability of treatments. Pharmalot